曲伏前列素滴眼液治疗原发性开角型青光眼的临床研究

发布时间：2018-07-23 16:48

【摘要】：目的观察曲伏前列素治疗原发性开角型青光眼(POAG)的临床疗效和安全性。方法将78例POAG患者随机分为对照组和试验组,每组39例。试验组予以给予曲伏前列素,药物的剂量均是每次1滴,每日1次;对照组予以盐酸左布诺洛尔,药物剂量为每次1滴,早晚各1次,每日2次,疗程均为3个月。比较2组患者治疗前、治疗后1个月和3个月眼压和血流动力学变化情况,以及药物不良反应的发生情况。结果治疗1个月后试验组和对照组7:00眼压分别为(15.51±2.11),(15.42±2.14)mm Hg,治疗前的水平分别为(24.98±3.24),(25.54±3.15)mm Hg,差异有统计学意义(P0.05)。与治疗前相比,治疗后3个月2组患者的每日5次眼压均有所降低;治疗后3个月,在21:00时,试验组患者的眼压为(15.16±3.25)mm Hg,对照组为(16.98±3.47)mm Hg,差异有统计学意义(P0.05)。治疗后,试验组的高切全血黏度、低切全血黏度、红细胞压积、血浆黏度、纤维蛋白原指标分别为(5.02±1.01)m Pa·s、(7.05±1.11)m Pa·s、(38.57±6.15)%、(1.46±0.16)m Pa·s、(2.58±0.65)g·L~(-1),对照组为(5.97±1.31)m Pa·s、(8.54±1.22)m Pa·s、(42.31±7.42)%、(1.57±0.18)m Pa·s、(3.43±0.71)g·L~(-1),差异有统计学意义(P0.05)。试验组患者出现睫毛生长2例,结膜充血4例,眼部疼痛1例,腹部痉挛性疼痛的患者1例,总药物不良反应发生率为20.51%(8/29例);对照组出现心率减慢2例,眼干2例,短暂性烧灼感4例,总药物不良反应发生率为20.51%(8/29例),差异无统计学意义(P0.05)。结论曲伏前列素滴眼液在控制夜间眼压、改善血流动力学、稳定性方面相对优于盐酸左布诺洛尔滴眼液,安全性较好。
[Abstract]:Objective To observe the clinical efficacy and safety of tratoprost in the treatment of primary open angle glaucoma (POAG). Methods 78 patients with POAG were randomly divided into a control group and a test group, with 39 cases in each group. The experimental group was given tratoprost with a dose of 1 drops each time and 1 times a day; the control group was given levoflol hydrochloride, the dose of the drug was every one. 1 drops, 1 times in the morning and evening, 2 times a day for 3 months. Compare the intraocular pressure and hemodynamic changes of the 2 groups before treatment, 1 months and 3 months after treatment, and the occurrence of adverse drug reactions. Results after 1 months, the intraocular pressure of the test group and the control group was (15.51 + 2.11), (15.42 + 2.14) mm Hg, and the level before treatment. The difference was statistically significant (24.98 + 3.24), (25.54 + 3.15) mm Hg (P0.05). Compared with before treatment, the daily pressure of 5 times per day in 2 groups of patients after treatment was reduced; at 21:00 after treatment, at 21:00, the intraocular pressure of the patients in the test group was (15.16 + 3.25) mm Hg, and the control group was (16.98 + 3.47) mm Hg, the difference was statistically significant (P0.05). After treatment, the difference was statistically significant. The high cut whole blood viscosity, low cut whole blood viscosity, red blood cell pressure, plasma viscosity, fibrinogen index were (5.02 + 1.01) m Pa. S, (7.05 + 1.11) m Pa. S, (38.57 + 6.15)%, (1.46 + 0.16) m Pa. S, (2.58 + 0.65) g L~ (-1), and the control group (5.97 + 1.31) 0.71) g. L~ (-1), the difference was statistically significant (P0.05). In the experimental group, there were 2 cases of eyelash growth, 4 cases of conjunctiva congestion, 1 cases of eye pain, 1 cases of abdominal spastic pain, 20.51% of total adverse drug reactions (8/29 cases); 2 cases of heart rate slowing in the control group, 2 cases of eye dry, 4 cases of transient cauterization, and the total adverse drug reaction in the control group. The rate was 20.51% (8/29), and the difference was not statistically significant (P0.05). Conclusion Travoprost Eye Drops is better than levo hydrochloric eye drops in controlling nocturnal intraocular pressure, improving hemodynamics and stability.
【作者单位】：丽水市中心医院眼科;
【基金】：丽水市中心科技基金资助项目(2013ZC021)
【分类号】：R775.2

【参考文献】